Diabetic Foot  >>  Cubicin (daptomycin)  >>  Phase 4
Welcome,         Profile    Billing    Logout  

2 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Cubicin (daptomycin) / Merck (MSD)
NCT00463801 / 2006-004664-31: Safety and Efficacy of Daptomycin for the Treatment of Complicated Skin and Skin-structure Infections

Terminated
4
52
Europe
Daptomycin
Novartis
Staphylococcal Skin Infections
11/07
 
NCT01133600: Outpatient Treatment of Gram Positive Wound Infections in the Diabetic Foot: A Pharmaco-economic Comparison of Daptomycin vs. Vancomycin Based Regimens

Terminated
4
6
US
Cubicin, Vancomycin
Clinical Alliance for Research & Education - Infectious Diseases, LLC., Cubist Pharmaceuticals LLC
Diabetic Foot
08/12
08/12

Download Options